top of page

Developing innovative therapies that bring new hope to patients with dilated cardiomyopathy (DCM) — that is the mission of CardioGenix.

CardioGenix-logo

Shaping the Future of

Cardiomyopathy

Your contributions accelerate Dilated Cardiomyopathy (DCM) drug development. Donors receive regular research updates and efficacy evaluation reports of your desired drug using our DCM mouse model.

Research Partner

100 USD+

 Priority Research Newsletter

Core Supporter

500 USD+

+ Acknowledgement in              Research Report

Special Partner

1,000 USD+

+ Efficacy evaluation 

    reports of your desired

    drug using our DCM mouse

    model

bottom of page